[https://www.matwings.com](https://www.matwings.com)

[https://syntelly.ru](https://syntelly.ru)

1. Модифицировать белки DNA-содержащих фагов, обитающих на суше, чтобы их белки (или бактерии, инфицированные ими) легко формировали biofilm с высоким альбедо.
2. Совместить эту рамку считывания с критичным геном для размножения, дающим преимущество (для закрепления в популяции и для стимуляции горизонтального переноса этого гена).
3. Сделать этот белок регулируемым (внешним воздействием), для контроля распространения в природе.

4. Ideally regulation must be temperature-sensitive. Low temperature ⇨ decrased aggregation and/or decreased albedo and/or the phage population collapses due to e.g. rendering the phages towards replication deficiency.

Цель: поскольку фаги-- это самые распространённые формы жизни на Земле, повысить отражательную способность суши для постепенного снижения температуры планеты.

MVP:

- Сделать прототип.
- Замерить альбедо в лабораторных условиях.
- Показать возможность распространения и горизонтального переноса.
- Показать возможность выключения.
- Распространить на локальной территории (остров). Протестировать.
- Начать распространять на территориях с низким альбедо.

Questions:

- Which phages are strictly bound to the ground (can't spread via water/atmosphere)?
- Which phages are capable of building biofilm/render bacteria to build biofilms?
- Which phages preferably infect a narrow range of species (prevent too wide distribution)?
- Which phages are easy to genetically manipulate?
- Which proteins of the biofilms can be modified?
- How can the proteins be modified to increase the albedo: what are the known aminoacid sequences that result in white/mirror-like color of the surfaces?
- Which proteins can be encoded in a reversed ORF in order to preserve, spread and horizontally transfer the trait in the population?
- What are the possibilities of regulation (ideally temperature-sensitive)?

|   |   |   |
|---|---|---|
|Developing Covalent Protein Drugs<br><br>via Proximity-Enabled Reactive Therapeutics|<<Developing Covalent Protein .pdf>>|Small molecule drugs binding to their targets in covalent mode, although historically being intentionally avoided by pharmaceu- tical researchers and industry, have resurged with great success in recent years.<br><br>Covalent bonding between drug and target offer multiple desirable features over noncovalent interactions of con- ventional drugs, including increased biochemical efficiency and potency, prolonged duration of action outlasting the drug phar- macokinetics, improved therapeutic index with reduced dosage and dosing frequency, complete inactivation of target, and op- portunity to inhibit intractable targets<br><br>In contrast to the blossoming of small molecule covalent drugs, the therapeutic potential of covalent protein drugs re- mains largely untapped. This gap is due to an inherent limitation<br><br>of natural proteins: they interact mainly through noncovalent in- teractions and lack the covalent reactivity toward natural amino acid residues of targets. In addition, the ubiquitous presence of amino acids in proteins, cells, and in vivo imposes a huge chal- lenge to achieve reaction selectivity toward the protein target. The key to develop covalent small molecule drugs has been to strike the right balance between reactivity and selectivity|